Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 10:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Tanezumab 10 mg Clear all
Terminated Phase 3 Interventional Results available

Tanezumab and Nerve Function In Arthritis Patients

NCT00863772
View directory record Official record
Conditions
Osteoarthritis
Interventions
tanezumab, Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
97
States / cities
Jonesboro, Arkansas • Aurora, Colorado • Centennial, Colorado + 42 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Sep 24, 2026, 10:15 AM EDT
Terminated Phase 2 Interventional Results available

A Long Term Study of the Safety of Tanezumab When Administered By Subcutaneous Injections

NCT00994890
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions
Tanezumab 2.5 mg, Tanezumab 5 mg, Tanezumab 10 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
100
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 70 more
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Sep 24, 2026, 10:15 AM EDT
Terminated Phase 3 Interventional Results available

Safety Extension Study Of Tanezumab When Administered By Subcutaneous Injection To Patients With Osteoarthritis

NCT01127893
View directory record Official record
Conditions
Osteoarthritis
Interventions
Tanezumab
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
La Mesa, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Sep 24, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

A Study Of Tanezumab as Add-On Therapy to Opioid Medication In Patients With Pain Due To Cancer That Has Spread To Bone

NCT00545129
View directory record Official record
Conditions
Neoplasm Metastasis, Palliative Care
Interventions
Tanezumab 10 mg IV, IV Placebo for tanezumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
12
States / cities
La Jolla, California • South Bend, Indiana • Shreveport, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2021 · Synced Sep 24, 2026, 10:15 AM EDT
Terminated Phase 3 Interventional Results available

Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip

NCT00809354
View directory record Official record
Conditions
Osteoarthritis, Arthritis
Interventions
NSAID, tanezumab
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
2,720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
250
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 161 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Sep 24, 2026, 10:15 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy And Safety Study Of Tanezumab Subcutaneous Administration In Osteoarthritis - A Subcutaneous/Intravenous Bridging Study

NCT01089725
View directory record Official record
Conditions
Osteoarthritis, Arthritis, Pain
Interventions
Placebo IV, Placebo SC, Tanezumab SC, Tanezumab IV
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
91
States / cities
Montgomery, Alabama • Mesa, Arizona • Phoenix, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Sep 24, 2026, 10:15 AM EDT
Terminated Phase 3 Interventional Results available

Extension Study Of Tanezumab In Osteoarthritis

NCT00809783
View directory record Official record
Conditions
Osteoarthritis
Interventions
tanezumab
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
2,147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
226
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 148 more
Source: ClinicalTrials.gov public record
Updated May 9, 2021 · Synced Sep 24, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

Tanezumab in Osteoarthritis of the Hip or Knee (2)

NCT00863304
View directory record Official record
Conditions
Osteoarthritis
Interventions
tanezumab 10 mg, tanezumab 5 mg, naproxen, placebo
Biological · Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
849 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
95
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated May 16, 2021 · Synced Sep 24, 2026, 10:15 AM EDT
Terminated Phase 2 Interventional Results available

Long Term Safety Study of Tanezumab in Chronic Low Back Pain

NCT00924664
View directory record Official record
Conditions
Low Back Pain
Interventions
Tanezumab 20 mg, Tanezumab 10 mg
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
849 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
149
States / cities
Anniston, Alabama • Birmingham, Alabama • Hueytown, Alabama + 99 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Sep 24, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

A Study of Tanezumab in Adults With Chronic Low Back Pain

NCT00876187
View directory record Official record
Conditions
Low Back Pain
Interventions
Tanezumab 20 mg IV, Placebo for naproxen, Tanezumab 10 mg IV, Tanezumab 5 mg IV, Placebo for tanezumab, Naproxen
Biological · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
135
States / cities
Anniston, Alabama • Birmingham, Alabama • Hueytown, Alabama + 101 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Sep 24, 2026, 10:15 AM EDT
Terminated Phase 3 Interventional Results available

Long-Term Study Of The Safety Of Tanezumab In Arthritis Patients

NCT00960804
View directory record Official record
Conditions
Osteoarthritis
Interventions
Tanezumab, Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
18
States / cities
Atlantis, Florida • Fort Myers, Florida • South Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2021 · Synced Sep 24, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

Tanezumab in Osteoarthritis Of The Hip

NCT00744471
View directory record Official record
Conditions
Arthritis, Osteoarthritis, Osteoarthritis, Hip
Interventions
tanezumab, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
627 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
99
States / cities
Mobile, Alabama • Paradise Valley, Arizona • Peoria, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Sep 24, 2026, 10:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Measure Exposure Of Tanezumab In Healthy Volunteers When Administering The Drug Subcutaneously

NCT00788294
View directory record Official record
Conditions
Healthy Volunteers
Interventions
tanezumab
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Sep 24, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of Tanezumab for Chronic Low Back Pain

NCT02528253
View directory record Official record
Conditions
Low Back Pain
Interventions
Placebo to Week 16; tanezumab 5mg SC, Placebo to Week 16, tanezumab 10 mg SC, Tanezumab 5 mg SC, Tanezumab 10 mg SC, Tramadol PR oral
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,832 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
179
States / cities
Birmingham, Alabama • Mobile, Alabama • Saraland, Alabama + 124 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Sep 24, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

Open Label Extension In Cancer Patients

NCT00830180
View directory record Official record
Conditions
Neoplasms, Bone Metastases
Interventions
Anti-NGF AB
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
6
States / cities
La Jolla, California • Shreveport, Louisiana • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 4, 2021 · Synced Sep 24, 2026, 10:15 AM EDT
Not listed Phase 2 Interventional

Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis

NCT04163419
View directory record Official record
Conditions
Schwannomatosis, Pain
Interventions
Tanezumab, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Sep 24, 2026, 10:15 AM EDT
Terminated Phase 3 Interventional Results available

Tanezumab In Osteoarthritis Of The Hip Or Knee

NCT00985621
View directory record Official record
Conditions
Osteoarthritis
Interventions
tanezumab 10 mg, tanezumab 5 mg, oxycodone, placebo
Biological · Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
66
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Sep 24, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

Tanezumab In Osteoarthritis Of The Knee (2)

NCT00830063
View directory record Official record
Conditions
Arthritis, Osteoarthritis
Interventions
tanezumab 10 mg, tanezumab 5 mg, naproxen, placebo
Biological · Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
832 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
94
States / cities
Anniston, Alabama • Mesa, Arizona • Paradise Valley, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Sep 24, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

Tanezumab in Osteoarthritis of the Knee

NCT00733902
View directory record Official record
Conditions
Arthritis, Osteoarthritis
Interventions
tanezumab, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
697 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
82
States / cities
Phoenix, Arizona • Danbury, Connecticut • Stamford, Connecticut + 65 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2021 · Synced Sep 24, 2026, 10:15 AM EDT
Terminated Phase 2 Interventional Results available

A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome

NCT00999518
View directory record Official record
Conditions
Cystitis, Interstitial
Interventions
Tanezumab, Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
122
States / cities
Mobile, Alabama • Glendale, Arizona • Phoenix, Arizona + 70 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Sep 24, 2026, 10:15 AM EDT